Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTempest raises $2M by slashing warrant price 51%, issues new warrants for 2.3M shares
Filed June 2, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
high
Company induced warrant exercise by cutting price from $3.50 to $1.73 per share, raising ~$2M gross but issuing new warrants for twice as many shares (2.3M), creating significant future dilution risk.
Item 1.01 verify on EDGAR → -
high
New warrants expire May 2028 and require shareholder approval before becoming exercisable. Include cashless exercise rights if shares aren't registered, meaning company may not receive cash from future exercises.
Item 1.01 verify on EDGAR → -
medium
Placement agent receives cascading compensation: immediate warrants for 82K shares plus 7% cash fee and 7% additional warrants on any new warrant exercises within 24 months, compounding dilution.
Item 1.01 verify on EDGAR → -
medium
Company must register new warrant shares for resale within 30-45 days, creating near-term selling pressure once warrants become exercisable after shareholder approval.
Item 1.01 verify on EDGAR → -
high
The 51% discount from original $3.50 warrant price to $1.73 suggests either urgent capital needs or significant stock decline since November 2025 warrant issuance.
Item 1.01 verify on EDGAR →
Summary
Tempest Therapeutics executed a warrant inducement transaction that raises immediate questions about the company's financial position. By slashing the exercise price 51% from the original $3.50 to $1.73, the company convinced a warrant holder to exercise 1.17 million warrants for approximately $2 million in gross proceeds.
However, the cost was steep: issuing new warrants for 2.34 million shares at the same reduced price, effectively doubling the warrant overhang. Retail investors should be concerned about the dilution math and what it signals. The company needed cash badly enough to accept a deal that creates more than twice the potential future dilution.
The new warrants include cashless exercise provisions, meaning Tempest may never see cash from those 2.3 million shares if they're exercised without a registration statement in effect. Add in the placement agent's cascading fees and warrants, and the total dilution could exceed 2.5 million shares. Watch for the shareholder vote required to activate these warrants and monitor whether the company can avoid further dilutive financings. If Tempest returns to the capital markets within the next 6-12 months, it would confirm that this $2 million raise was a stopgap rather than a solution.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The New Warrant has an exercise price of $1.73 per share, will become exercisable on the effective date of stockholder approval required under the applicable rules of The Nasdaq Capital Market with respect to the issuance of the shares underlying the New Warrant, and will expire on May 29, 2028. The New Warrant contains customary adjustment provisions for stock dividends, stock splits, reorganizations and similar events, customary beneficial ownership limitations of either 4.99% or 9.99% at the holder’s election, and cashless exercise rights if a registration statement covering the resale of the underlying shares is not then effective.
The new warrants expire in two years (May 2028) and require shareholder approval before becoming exercisable, per Nasdaq rules. They include cashless exercise provisions if shares aren't registered, meaning the company may not receive cash proceeds from future exercises. The beneficial ownership caps (4.99% or 9.99%) provide some protection against concentrated ownership but don't limit overall dilution.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Tempest Therapeutics disclosed unregistered sales of equity securities, with details cross-referenced to Item 1.01.
Added in current filing · verify on EDGAR →
The information contained in Item 1.01 of this Current Report on Form 8-K regarding the unregistered securities described therein is incorporated by reference in this Item 3.02.
The company disclosed unregistered sales of equity securities under Item 3.02, but the actual details are cross-referenced to Item 1.01 of the same 8-K filing. Without access to Item 1.01, the specific terms, amounts, and parties involved in the equity issuance cannot be determined from this excerpt alone.
Event · Item 9.01 — Financial Statements and Exhibits
Tempest Therapeutics disclosed warrant exercise inducement agreements and issuance of new warrants with placement agent warrants.
Added in current filing · verify on EDGAR →
Form of Warrant Exercise and Inducement Offer Letter
The company entered into warrant exercise and inducement agreements, typically used to encourage existing warrant holders to exercise their warrants early in exchange for new warrants or other consideration. This is a financing mechanism that can raise immediate cash while potentially diluting existing shareholders through the issuance of new warrants.
Added in current filing · verify on EDGAR →
Form of New Warrant
The company issued new warrants, likely as part of the inducement offer to existing warrant holders. New warrants represent potential future dilution to shareholders if exercised, though the specific terms (strike price, expiration, number of shares) are not disclosed in this 8-K body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Form of Placement Agent Warrant
The company issued warrants to a placement agent as compensation for facilitating the warrant exercise transaction. This is standard practice in private placements and warrant inducement transactions, representing additional potential dilution and transaction costs.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify